Label: Information for the User

Cefuroxima Reig Jofre 250 mg Powder and Diluent for Injectable Solution EFG

Read this label carefully before starting to use this medication, as it contains important information for you.

• Keep this label, as you may need to refer to it again.
• If you have any questions, consult your doctor, pharmacist, or nurse.
• If you experience any adverse effects, consult your doctor or nurse, even if they are not listed in this label. See section 4.

Cefuroxima Reig Jofre is an antibiotic used in both adults and children. It works by eliminating the bacteria that cause infections. It belongs to the group of medications known ascephalosporins.

Cefuroxima Reig Jofre is used to treat infections of:.

• the lungs or chest,
• the urinary tract,
• the skin and soft tissues,
• the abdomen.

Cefuroxima Reig Jofre is also used for:

• preventing infections during surgical procedures.

No use Cefuroxima:

• if you are allergic (hypersensitive) to cephalosporinsor to any of the other components of this medication (listed in section 6).
• if you have ever had a severe allergic reaction (hypersensitive) to any other type of beta-lactam antibiotic (penicillins, monobactams, and carbapenems).
• if you have ever developed severe skin rash or peeling, blisters, and/or mouth ulcers after treatment with cefuroxima or any other cephalosporin antibiotic.

Consult with your doctor beforestarting treatment with cefuroxima; if you consider this may affect you, Cefuroxima Reig Jofre should not be administered to you.

Warnings and precautions

You should be aware of certain symptoms such as allergic reactions and gastrointestinal disturbances, such as diarrhea, while receiving cefuroxima. This will reduce the risk of possible complications. See (“Symptoms to be aware of”) in section 4. If you have had any allergic reaction to other antibiotics, such as penicillin, you may also be allergic to Cefuroxima Sala.

Severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), have been associated with treatment with cefuroxima. Seek medical attention immediately if you notice any of the symptoms related to these severe skin reactions described in section 4.

If you need blood or urine tests

Cefuroxima may affect the results in the determination of sugar in urine and blood (Coombs test). If you are undergoing tests:

Inform the person taking the samplethat you are receiving cefuroxima.

Use of Cefuroxima Reig Jofre with other medications

Inform your doctor or pharmacist if you are taking another medication, if you have taken recently or may have to take any other medication.

Some medications may affect the way cefuroxima acts, or make it more likely that you may have adverse effects. These include:

• aminoglycoside antibiotics,
• “urine-voiding” medications (diuretics), such as furosemide,
• probenecid,
• oral anticoagulants.

Consult with your doctorif you think this may affect you. You may need additional reviews to monitor renal function while taking cefuroxima.

Birth control pill

Cefuroxima may reduce the effectiveness of the birth control pill. If you are taking the birth control pill while being treated with cefuroxima, you should use additional barrier methods (such as condoms). Ask your doctor for advice.

Pregnancy, breastfeeding, and fertility

Inform your doctor before being treated with cefuroxima:

• if you are pregnant, think you may be pregnant, or intend to become pregnant,
• if you are breastfeeding.

Your doctor will assess the benefit of being treated with cefuroxima against the risk to your child.

Driving and operating machinery

Do not drive or operate machinery if you are not feeling well.

Cefuroxima Reig Jofre contains sodium:

A vial of cefuroxima Reig Jofre 250 mg contains 14 mg (0.59 mmol) of sodium, which is considered essentially “sodium-free.”

Two vials of Cefuroxima Reig Jofre 250 mg contain 28 mg (1.12 mmol) of sodium, which should be taken into account in patients with low-sodium diets.

Cefuroxima is usually administered by a doctor or nurse. It may be administered through direct injection into a vein or muscle.

Normal Dose

Your doctor will decide on the optimal dose of cefuroxima for you, based on: the severity and type of infection, if you are being treated with other antibiotics, your weight and age, and how well your kidneys are functioning.

Newborns (0 - 3 weeks)

For every kilogram of the newborn's weight, 30 to 100 mg of cefuroxima will be administered per day, divided into two or three doses.

Infants (over 3 weeks) and children

For every kilogram of the baby's or child's weight, 30 to 100 mg of cefuroxima will be administered per day, divided into three or four doses.

Adults and adolescents

750 mg to 1,500 mg of cefuroxima per day, divided into two, three, or four doses. The maximum dose is 6 g per day.

Patients with kidney problems

If you have a kidney problem, your doctor may adjust your dose.Consult with your doctorif you are affected by this problem.

Like all medicines, this medicine can cause side effects, although not everyone will experience them.

Symptoms to be aware of

A small number of people who received cefuroxime presented an allergic reaction or a potentially severe skin reaction. The symptoms of these reactions include:

• Severe allergic reaction. The signs includeskin rash with itching, swelling, sometimes on the face or mouth, causingdifficulty breathing,
• Skin rash,which may causeblistering,appearing assmall, dark spots (a dark spot in the center surrounded by a lighter area, with a dark ring around the edge),
• Widespread skin rash,withblistering and skin peeling.(These may be symptoms ofStevens-Johnson Syndromeortoxic epidermal necrolysis),
• Fungal infectionsin rare cases, medicines like cefuroxime can cause an overgrowth of fungi (Candida) in the body that may lead to fungal infections (such as mouth ulcers). This side effect is more likely to occur if you have been treated with cefuroxime for a prolonged period.
• Generalized rash, high body temperature, and swollen lymph nodes (DRESS syndrome or drug hypersensitivity syndrome).
• Chest pain in the context of allergic reactions, which may be a symptom of an allergic-induced heart attack (Kounis syndrome).

Contact your doctor or nurse immediately if you experience any of these symptoms.

Common side effects

May affectup to 1 in 10 people:

• Pain, swelling, and redness along the vein at the injection site.

Contact your doctorif you experience any of these symptoms.

Common side effects that may appear in blood tests:

• Increased levels of certain substances (enzymes) produced by the liver,
• Changes in white blood cell count (neutropeniaoreosinophilia),
• Low levels of red blood cells (anemia).

Uncommon side effects

May affectup to 1 in 100 people:

• Skin rash, itching, hives (urticaria),
• Diarrhea, nausea, stomach pain.

Contact your doctorif you experience any of these symptoms.

Uncommon side effects that may appear in blood tests:

• Low levels of white blood cells (leucopenia),
• Increased levels of bilirubin (a substance produced by the liver),
• Positive Coombs test.

Other side effects

Other side effects have occurred in a very small number of people, but their exact frequency is unknown:

• Fungal infections,
• High temperature (fever),
• Allergic reactions,
• Colitis (inflammation of the large intestine), causing diarrhea, usually with blood and mucus,
• Stomach pain,
• Inflammation in the kidneys and blood vessels,
• Rapid destruction of red blood cells (hemolytic anemia),
• Skin rash, which may cause blistering, appearing as small, dark spots (a dark spot in the center surrounded by a lighter area, with a dark ring around the edge)erythema multiforme.

Contact your doctorif you experience any of these symptoms.

Side effects that may appear in blood tests:

• Decreased platelet count in the blood (cells that help blood to clot –thrombocytopenia),
• Increased levels of urea nitrogen and creatinine in the blood.

Reporting side effects

If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use: https//www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.

Keep this medication out of the sight and reach of children.

Do not use this medication after the expiration date that appears on the box after CAD.

The expiration date is the last day of the month indicated.

Store below 30°C.

Store the vial in the outer packaging to protect it from light.

For the storage conditions of the reconstituted powder, see “INFORMATION FOR THE HEALTHCARE PROFESSIONAL” at the end of the leaflet.

Medicines should not be disposed of through the drains or in the trash. Dispose of the containers and medicines you no longer need at the SIGRE collection point of the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medicines you no longer need. By doing so, you will help protect the environment.

Cefuroxima Reig Jofre Composition:

The active ingredient is cefuroxime sodium.

Each vial of 250 mg contains Reig Jofre 267.37 mg of cefuroxime sodium equivalent to 250 mg of cefuroxime.

The ampoule of solvent contains water for injection preparations

Appearance of Cefuroxima Reig Jofre and packaging contents:

Cefuroxime sodium is a white or pale yellow powder.

It is presented in transparent type II glass vials of 10 ml capacity, closed with a grey bromobutyl rubber stopper and sealed with a "flip-off" capsule.

Ampoule of solvent of type I glass containing 2 ml of injection water.

Packaging of 1 vial and 1 ampoule of solvent.

Marketing authorization holder and responsible for manufacturing:

Marketing authorization holder:

Reig Jofré, S.A.

Gran Capitán 10, 08970 Sant Joan Despí

Barcelona (Spain)

Responsible for manufacturing:

Laboratorio Reig Jofre, S.A

Jarama 111Industrial Estate, Toledo

45007 Toledo

Last review date of this leaflet:May 2023

The detailed and updated information of this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/

-----------------------------------------------------------------------------------------------------------------

INFORMATIONFOR THE HEALTHCARE PROFESSIONAL

Instructions for reconstitution:

For single use. Discard unused solution.

Intramuscular use:

Add 1 ml of injection water to cefuroxime 250 mg powder for injection solution (see "Volumes of addition and concentrations of the solution, which may be useful when fractional doses are required" table).

Gently shake to obtain an opaque suspension.

Intravenous use:

Dissolve in injection water using at least 2 ml for cefuroxime 250 mg. Gently shake to obtain a transparent solution.

Volumes of addition and concentrations of the solution, which may be useful when fractional doses are required

** The resulting volume of the cefuroxime solution in the reconstitution medium is increased by the displacement factor of the resulting drug in the listed concentrations in mg/ml.

Compatibility:

Cefuroxime sodium is compatible with aqueous solutions containing up to 1% lidocaine hydrochloride.

The stability of cefuroxime sodium in sodium chloride 0.9% solution for injection and in 5% glucose solution for injection is not affected by the presence of hydrocortisone phosphate sodium.

Storage of injectable cefuroxime:

Store below 30°C.

Store the vial in the outer packaging to protect it from light.

Reconstituted solution: From a microbiological point of view, once opened, the product should be used immediately. If not used immediately, the storage times in use and the conditions prior to use are the responsibility of the user and should not normally be greater than8 hours at 25°C and 24 hours in the refrigerator (between 2°C and 8°C), unless the reconstitution was performed in controlled and validated conditions.

Incompatibilities:

Solutions containing cefuroxime should not be mixed with or added to solutions containing other products that are not mentioned above (See "Compatibility").

Cefuroxime powder for injection solution should not be mixed in the same syringe with aminoglycoside antibiotics.

The pH of sodium bicarbonate injection 2.74% p/v significantly affects the color of the solutions and is therefore not recommended for diluting cefuroxime powder for injection solution.